Anemarrhenae Rhizoma Shows Promising Effects in Treating Type 2 Diabetes Mellitus

Strategic Insights -

A recent study published in Frontiers in Endocrinology has revealed the potential of Anemarrhenae Rhizoma (AR) in treating type 2 diabetes mellitus (T2DM). The researchers employed an integrated strategy combining metabolomics with serum-urine pharmacochemistry and network pharmacology to identify the active constituents and elucidate the mechanisms of AR in managing T2DM. The study found that AR treatment significantly reduced blood glucose and lipid levels, ameliorated insulin resistance, and modulated the PPAR and NF-kB signalling pathways.

Key Takeaways:

  • The study identified 77 AR components, among which 47 prototypes and 11 metabolites were detected in serum and urine.
  • The key bioactive constituents included sarsasapogenin, markogenin/neogitogenin, digitogenin, norathyriol, and mangiferin.
  • AR treatment significantly reduced blood glucose and lipid levels, and ameliorated insulin resistance, with a concomitant attenuation of inflammation and modulation of the PPAR and NF-kB signalling pathways.
  • The study also revealed that serum metabolomics analysis revealed 35 differential metabolites, with linoleic acid metabolism and PPAR signalling identified as the predominant metabolic pathways.
  • The researchers concluded that AR ameliorates T2DM by suppressing NF-kB signalling and activating PPAR pathways.

Statistics:

  • 77 AR components were identified in the study.
  • 47 prototypes and 11 metabolites were detected in serum and urine.
  • 35 differential metabolites were revealed in serum metabolomics analysis.
  • The study found that AR treatment significantly reduced blood glucose levels by X% and lipid levels by Y%.

Sources:

  • "Metabolomics integrated with network pharmacology and serum-urine pharmacochemistry unveils the antidiabetic mechanism of Anemarrhenae Rhizoma." Frontiers in Endocrinology, 2025,16. (Frontiers in Endocrinology - http://www.frontiersin.org/endocrinology)
  • Health & Medicine Week, October 31, 2025; p 6172.